ACP
DAWN

Altitude Crest Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Altitude Crest Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-195,497
Closed -$3.23M – 9
2024
Q1 		$3.23M Buy
+195,497
New +$2.93M 1.38% 22

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Altitude Crest Partners's DAWN Position: Q2 2024 in Review

Altitude Crest Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2024, closing a stake of 195,497 shares — an estimated $3.23M sold.

Altitude Crest Partners first reported a position in DAWN in Q1 2024 and held it in 1 quarter. The position peaked at $3.23M in Q1 2024. 156 funds tracked by Wall St. Rank hold DAWN as of Q2 2024.

  • Altitude Crest Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 195,497 Day One Biopharmaceuticals shares in Q2 2024, an estimated $3.23M.
  • Altitude Crest Partners first reported a position in Day One Biopharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Day One Biopharmaceuticals position peaked at $3.23M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.